Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8442020 | 1.00 | MEN1 (0.51) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL31076183 | 1.00 | MEN1 (0.51) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL11354372 | 1.00 | MEN1 (0.51) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL11517500 | 0.99 | MEN1 (0.49) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL5214341 | 0.96 | MEN1 (0.49) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Iodide SCHEMBL7755123 | 0.93 | MEN1 (0.49) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL7324390 | 0.91 | KDM4C (0.47) | MEN1KMT2AKDM4CCHRNA7L3MBTL1 | |
| Iodide SCHEMBL28851041 | 0.88 | MEN1 (0.46) | MEN1KMT2AKDM4CCHRNA7PSMB1 | |
| Bromide SCHEMBL31076166 | 0.85 | MEN1 (0.42) | MEN1KMT2AKDM4CCHRNA7L3MBTL1 | |
| Bromide SCHEMBL23387051 | 0.83 | CHRNA7 (0.36) | MEN1KMT2AKDM4CCHRNA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006464-B2 | Substituted cyclopentanes having prostaglandin activity | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2217581-B1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDINE ACTIVITY | ALLERGAN INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2217581-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDING ACTIVITY | ALLERGAN, INC. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061811-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDING ACTIVITY | ALLERGAN, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090124676-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124676-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | MEN1 4466/4885KMT2A 4817/4885KDM4C 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.